A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors

por Doi, Toshihiko, Tajimi, Masaomi, Mori, Joji, Asou, Hiroya, Inoue, Koichi, Benhadji, Karim A., Naito, Yoichi
Publicado 2020

Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon

por Collins, Michael, Michot, Jean-Marie, Bellanger, Christophe, Mussini, Charlotte, Benhadji, Karim, Massard, Christophe, Carbonnel, Franck
Publicado 2021

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma

por Ikeda, Masafumi, Morimoto, Manabu, Tajimi, Masaomi, Inoue, Koichi, Benhadji, Karim A., Lahn, Michael M. F., Sakai, Daisuke
Publicado 2018

Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial

por Ghidini, Michele, Hochster, Howard, Doi, Toshihiko, Van Cutsem, Eric, Makris, Lukas, Takahashi, Osamu, Benhadji, Karim A., Mansoor, Wasat
Publicado 2023

Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS)

por Shitara, Kohei, George, Ben, Taieb, Julien, Sundar, Raghav, Fakih, Marwan G., Makris, Lukas, Benhadji, Karim A., Ghidini, Michele
Publicado 2023

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients

por Serova, Maria, Tijeras-Raballand, Annemilaï, Santos, Célia Dos, Albuquerque, Miguel, Paradis, Valerie, Neuzillet, Cindy, Benhadji, Karim A., Raymond, Eric, Faivre, Sandrine, de Gramont, Armand
Publicado 2015

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

por Harding, James J., Do, Richard K., Yaqubie, Amin, Cleverly, Ann, Zhao, Yumin, Gueorguieva, Ivelina, Lahn, Michael, Benhadji, Karim A., Kelley, Robin K., Abou‐Alfa, Ghassan K.
Publicado 2021

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint i...

por Schaer, David, Li, Yanxia, Castaneda, Stephen, Inigo, Ivan, Surguladze, David, Xu, Xiaohong, Nugent, Desiree, Murphy, Mary, Hall, Gerald, Benhadji, Karim, Guba, Susan, Li, Yiwen, Kalos, Michael, Driscoll, Kyla
Publicado 2015

A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations

por Piha-Paul, Sarina A., Azaro, Analía, Arkenau, Hendrik Tobias, Oh, Do-Youn, Galsky, Matthew D., Pal, Sumanta Kumar, Hamada, Kensuke, He, Yaohua, Yamamiya, Ikuo, Benhadji, Karim A, Hollebecque, Antoine
Publicado 2021

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib

por Giannelli, Gianluigi, Santoro, Armando, Kelley, Robin K., Gane, Ed, Paradis, Valerie, Cleverly, Ann, Smith, Claire, Estrem, Shawn T., Man, Michael, Wang, Shuaicheng, Lahn, Michael M., Raymond, Eric, Benhadji, Karim A., Faivre, Sandrine
Publicado 2020

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib

por Giannelli, Gianluigi, Santoro, Armando, Kelley, Robin K., Gane, Ed, Paradis, Valerie, Cleverly, Ann, Smith, Claire, Estrem, Shawn T., Man, Michael, Wang, Shuaicheng, Lahn, Michael M., Raymond, Eric, Benhadji, Karim A., Faivre, Sandrine
Publicado 2021

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

por Meric-Bernstam, Funda, Bahleda, Rastislav, Hierro, Cinta, Sanson, Marc, Bridgewater, John, Arkenau, Hendrik-Tobias, Tran, Ben, Kelley, Robin Kate, Park, Joon Oh, Javle, Milind, He, Yaohua, Benhadji, Karim A., Goyal, Lipika
Publicado 2022

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

por Herbertz, Stephan, Sawyer, J Scott, Stauber, Anja J, Gueorguieva, Ivelina, Driscoll, Kyla E, Estrem, Shawn T, Cleverly, Ann L, Desaiah, Durisala, Guba, Susan C, Benhadji, Karim A, Slapak, Christopher A, Lahn, Michael M
Publicado 2015

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

por Yamamoto, Nobuyuki, Hayashi, Hidetoshi, Planchard, David, Morán, Teresa, Gregorc, Vanesa, Dowell, Jonathan, Sakai, Hiroshi, Yoh, Kiyotaka, Nishio, Makoto, Cortot, Alexis B., Benhadji, Karim A., Soni, Nital, Huang, Jinhong, Makris, Lukas, Cedres, Susana
Publicado 2020

Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 s...

por Shitara, Kohei, Doi, Toshihiko, Hosaka, Hisashi, Thuss-Patience, Peter, Santoro, Armando, Longo, Federico, Ozyilkan, Ozgur, Cicin, Irfan, Park, David, Zaanan, Aziz, Pericay, Carles, Özgüroğlu, Mustafa, Alsina, Maria, Makris, Lukas, Benhadji, Karim A., Ilson, David H.
Publicado 2022

A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations

por Rodón, Jordi, Funchain, Pauline, Laetsch, Theodore W, Arkenau, Hendrik-Tobias, Hervieu, Alice, Singer, Christian F, Murciano-Goroff, Yonina R, Chawla, Sant P, Anthony, Kristin, Yamamiya, Ikuo, Liu, Mei, Halim, Abdel-Baset, Benhadji, Karim A, Takahashi, Osamu, Delaloge, Suzette
Publicado 2022

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

por Melisi, Davide, Garcia-Carbonero, Rocio, Macarulla, Teresa, Pezet, Denis, Deplanque, Gael, Fuchs, Martin, Trojan, Jorg, Oettle, Helmut, Kozloff, Mark, Cleverly, Ann, Smith, Claire, Estrem, Shawn T., Gueorguieva, Ivelina, Lahn, Michael M. F., Blunt, Al, Benhadji, Karim A., Tabernero, Josep
Publicado 2018

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

por Nadal, Ernest, Saleh, Mansoor, Aix, Santiago Ponce, Ochoa-de-Olza, Maria, Patel, Sandip Pravin, Antonia, Scott, Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Estrem, Shawn T., Liu, Jiangang, Avsar, Emin, Lin, Wen Hong, Benhadji, Karim A., Gandhi, Leena, Guba, Susan C., Diaz, Inmaculada Ales
Publicado 2023

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

por Melisi, Davide, Oh, Do-Youn, Hollebecque, Antoine, Calvo, Emiliano, Varghese, Anna, Borazanci, Erkut, Macarulla, Teresa, Merz, Valeria, Zecchetto, Camilla, Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Gandhi, Leena, Estrem, Shawn T, Benhadji, Karim A, Lanasa, Mark C, Avsar, Emin, Guba, Susan C, Garcia-Carbonero, Rocio
Publicado 2021

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combinat...

por Holmgaard, Rikke B., Schaer, David A., Li, Yanxia, Castaneda, Stephen P., Murphy, Mary Y., Xu, Xiaohong, Inigo, Ivan, Dobkin, Julie, Manro, Jason R., Iversen, Philip W., Surguladze, David, Hall, Gerald E., Novosiadly, Ruslan D., Benhadji, Karim A., Plowman, Gregory D., Kalos, Michael, Driscoll, Kyla E.
Publicado 2018